InvestorsHub Logo
Followers 292
Posts 76049
Boards Moderated 3
Alias Born 03/20/2013

Re: None

Sunday, 12/17/2017 8:58:30 PM

Sunday, December 17, 2017 8:58:30 PM

Post# of 21373
M.D. ANDERSON'S PRE-CLINCAL TRIAL "ONCOLIX" PROLANTA (G129R) http://nebula.wsimg.com/5542c0afba149bcb25b0b56a5099a065?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

Conclusion (lower left-hand corner): G129R functions as a molecular
antagonist to tumor-associated PRL by inducing
adaptive autophagic cell death in human ovarian cancer
.
These preclinical findings reveal the novelty of G129R as
an adjuvant therapy for ovarian cancer

CONCLUSIONS (LOWER RIGHT-HAND CORNER)
1. Prolactin antagonist, G129R, inhibits ovarian cancer growth and
progression
;
2. PRLR is required for G129R induced autophagy;
3. PEA-15 mediates autophagic cell death induced by blocking
PLR/PRLR signaling;

Prolanta™ (referenced in the scientific literature as G129R): https://www.oncolixbio.com/prolanta-structure.html

Prolanta: https://www.oncolixbio.com/home.html

"The stock market is a device for transferring money from the impatient to the patient" — Warren Buffett

"The Big Money is not in the buying and the selling but in the waiting" — Charlie Munger

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.